Screener
Denali Therapeutics Inc. DNLI Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:08 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001714899-26-000097
FAQ
- What is Denali Therapeutics Inc.'s net income?
- Denali Therapeutics Inc. (DNLI) reported net income of -$127.55M in Q2 2026.
- How has Denali Therapeutics Inc.'s net income changed year-over-year?
- Denali Therapeutics Inc.'s net income decreased by 2.8% year-over-year, from -$124.12M to -$127.55M.
- What is the long-term trend for Denali Therapeutics Inc.'s net income?
- Over 4 years (2021 to 2025), Denali Therapeutics Inc.'s net income has grown at a 15.2% compound annual growth rate (CAGR), from -$290.58M to -$512.54M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Denali Therapeutics Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude